


NEXUS / PORTAL

The digital patient support



QUARTERLY STATEMENT

01ST JANUARY TO 30TH OF SEPTEMBER 2022

Financial Highlights for the 3rd Quarter 2022 and 2021

	30/09/2022	30/09/2021	Change
Sales and operating result	KEUR	KEUR	(in %)
Sales	150,790	137,223	9.9
Segment revenues Healthcare Software (unconsolidated)	146,378	132,002	10.9
Segment revenues Healthcare Service (unconsolidated)	6,719	9,966	-32.6
Domestic sales	79,239	73,955	7.1
Sales in foreign countries	71,551	63,268	13.1
EBITDA	31,236	27,605	13.2
EBITA	22,351	18,639	19.9
EBIT	18,794	15,140	24.1
EBT	17,879	14,326	24.8
Consolidated net income	13,845	11,110	24.6
Cash flow from operating activities	30,948	24,727	25.2
Earnings per share (undiluted/diluted) in EUR	0.86	0.69	24.6
Ongoing development costs and depreciations			
Capitalization of software developments	1,773	2,015	-12.0
Total depreciation	12,442	12,465	-0.2
Acquisition-related depreciation from purchase price allocation	3,557	3,499	1.7
Assets and equity capital			
Non-current assets	184,256	181,118	1.7
Current assets	149,412	66,223	125.6
Liquid assets (incl. shortterm finance disposition)	109,783	26,172	319.5
Equity capital	234,931	142,403	65.0
Share price (closing price, Xetra, in EUR)	47.75	71.50	-33.2
Employees (quarterly average)	1,544	1,445	6.9

¹⁾ Key date 31/12/2021

As rounded figures are used in this report, it is possible that the totals and calculated percentage figures may vary slightly.

Letter to our Shareholders

Dear Shareholders:

The nine-month view of our business remains contradictory. War, inflation, pandemic, energy crisis, stock market crash and shortage of skilled workers:

the macro level could hardly appear gloomier.

This contrasts with strong quarterly figures, high cash flow, record new orders and a successfully placed capital increase: The first nine months of 2022 were **very positive for NEXUS.**

There is also reason for **optimism** in the long term. The current government programs for the digitalization of the healthcare system offer us the unique opportunity to **significantly increase** our sales and market shares in the coming years. The hospitals in Germany and France are currently awarding large orders under the **Hospital Future Act (KHZG)** and **SEGUR programs**, and investments in e-health applications are also increasing in other countries.

As well as we are doing in the current difficult situation, the consequences of crises affect us at critical points. Inflation is driving up our **staff and energy costs** significantly, the high **sickness rates**, home office and quarantine rules are making our service business more difficult, and the shortage of skilled workers remains a major **challenge** in all areas.

All in all, this is a challenging starting point, which requires a high level of vigilance on the part of the entire NEXUS team.

Results


In this environment, it was not a matter of course to deal with matters successfully in the current period. We are all the more pleased that we were again able to show a very convincing increase in sales and earnings in the third quarter of 2022. We were able to successfully continue the development of continuously increasing sales and profits which has lasted for more than two decades.

In the first nine months of the year, our sales increased by approx. 10% compared to the previous year to KEUR 137,223 while earnings before interest and taxes (EBIT) rose by approx. 24 % to KEUR 18,794. With **EBITDA of approx. KEUR 31,236 (+13.2%)** and cash flow from operating activities of KEUR 30,948 (+25.2%), we were again able to present a very strong result in the third quarter. The **result per share increased by 24.6%** from EUR 0.69 (9M 2021) to EUR 0.89.



___ Dr. Ingo Behrendt, Chief Executive Officer (CEO)

The sales figures include company acquisitions for the current year amounting to KEUR 5,359 consolidated. EBITDA increased by KEUR 350 as a result of these consolidations. It should be noted that the sales and results of NEXUS / DIGITAL PATHOLOGY GmbH have been integrated in the laboratory business segment and are therefore no longer reported as acquired revenues. The special hardware sales of KEUR 1,839 in the "Deutsche Rente project in the previous year were a one-off effect that was adjusted to calculate the organic sales comparison. Adjusted for these two effects, organic sales increased by approx. 8% and organic EBITDA increased by approx. 12%. Currency effects were mainly caused by the stronger Swiss franc and the weaker Polish zloty and contributed a total of KEUR 1.876 to sales and KEUR 403 to earnings.



Market

In terms of sales, we focused on processing bid invitations from national funding programs in the first nine months of 2022. We posted significant new orders here in Germany and France. It is gratifying that we have also been able to win large new orders in addition to those in these programs. These include two new HIS customers in Germany, a major project in the Netherlands, numerous diagnostic projects in German university hospitals and two large orders from Lower Austria for QM software and digital pathology.

It is obvious that the market trusts **our products and our company**. In a competitive environment characterized by many changes, we have a market advantage as a stable and reliable company. Just in the last few weeks, some market participants have published changes to their strategy and product discontinuations. This is a **chance** for us; We are available with modern systems as a reliable alternative.

Products

We will continue to focus strongly on our innovation projects in the remaining months to the end of the year. We are currently focusing on the organic expansion of our business. Hospitals are ready to invest in innovative and cost-saving solutions. The key success factor in this market are software solutions that make work easier for users and give them a positive user experience (UX). This aspect is particularly obvious against the background of the shortage of nursing staff and doctors.

That is why it is important to speed up our new developments. We are especially focusing on "NEXUS / ADVANCED REPORTING". This module supports the creation of findings texts and diagnoses based on image analyses, predefined terminologies and experience (AI). As a result, findings can be produced significantly faster and in higher quality. Starting with demanding endoscopic, cardiological and radiological findings, we will use the module in all our software applications across the board and internationally in the future. We are convinced of the success of this development and speak resolutely of a leap in efficiency and quality in clinical informatics. We are proud that we have already received the first international orders for this module. Other very important modules are "NEXUS / PORTAL", which improves the digital communication between practitioners and patients, and "NEXUS / VNA, i.e., clinic-wide image and document archiving, which enables a complete view of patient records.

Acquisitions and capital increase

We were able to recruit five smaller, highly specialized teams in the first nine months of 2022, which strengthen our "Laboratory" business segment and our Swiss subsidiary. We have held a 60% interest in oneICT AG since February 2022. The company is strengthening NEXUS / Schweiz in the area of ICT services. We have strengthened our "Laboratory" business segment by acquiring 70% of the shares in IFMS GmbH, Saarbrücken as of 31/05/2022 and an asset deal on the business operations of On-Lab GmbH, Offenburg as of 02/05/2022. Both highly specialized teams enable us to serve the laboratory and pathology market even more broadly and expand our position.

We want to continue this **form of company acquisitions** to acquire know-how, technologies and market access. This is a strategy that further strengthens our product portfolio and our customer loyalty.

For this purpose, we decided on 30/08/2022 on a cash capital increase to the exclusion of subscription rights. Utilizing authorized capital from 2021, the share capital was increased by approx. 9.17% from EUR 15,814,695.00 by EUR 1,450,000.00 to EUR 17,264,695.00 against cash contributions by issuing up to 1,450,000 new bearer shares with a pro rata amount of EUR 1.00 per share ("new shares"). We were able to acquire the company Luxembourg S.A. as a new shareholder, which

subscribed to the new shares at a placement price of EUR 50.00 each. As a result, Luxembourg S.A. holds approx. 8.4% of the shares of Nexus AG. A total of MEUR 72.5 of capital has been invested in our company, which will be used for further growth in the coming year. Our expansion strategy is especially focusing on internationalization and product innovations.

With Luxembourg S.A., NEXUS has been able to acquire a long-term anchor shareholder, which will closely accompany our company in this growth phase. Luxembourg is an investment company listed in Luxembourg with a total portfolio of around € 2.1 billion, specializing in long-term investments in growth companies.

Prof. Dr. rer. Oec Alexander Pocsay has resigned his position as Supervisory Board of Nexus AG in this connection. Mr. Florian Herger has joined the Supervisory Board of Nexus AG. Mr. Herger is Senior Investment Manager of Luxembourg S.A.

Highlights Q3 2022 – Company development

- + Strong sales increase in the third quarter +9,9%
- + National e-health projects in the tender phase
- + Large tenders won again
- + Strong increase in turnover in foreign markets

OUTLOOK: We Remain Optimistic

The year 2022 has been a challenging but successful one so far. With an approx. **10% increase in sales** and a **24% increase in EBIT**, we have demonstrated strong continuation of our uninterrupted growth. The large projects we are currently winning and implementing make us confident that we will remain successful in the futures.

We presented our outlook until 2026 at this year's Berenberg German Corporate Conference. We remain very optimistic for the period up to 2026. Thanks to the positive market environment in the digitalization of the healthcare system and the numerous government funding programs, we expect average organic growth of 8-9% p.a. until 2026. The key to this assessment is our strong product positioning and the focus on interoperability of our systems. In addition, we plan to achieve further growth through company acquisitions. The available liquid funds of approx. EUR 110 are to be used for further European acquisitions in the healthcare market.


Our outlook assumes that the business consequences of the numerous crises for NEXUS will remain small in the future. We are prepared for dealing with them. Especially with respect to costs for staff and energy, we must continuously evaluate further developments and make adjustments there if necessary. NEXUS is in a good position: We are well-positioned financially and do not depend on any critical value chains. As a result, we can focus on managing remaining risks.

The NEXUS team continues to look forward to these great challenges.

Warm regards,



Dr. Ingo Behrendt
Chief Executive Officer



Interim Annual Report

Report about the profit, financial and asset situation

NEXUS Group sales increased from KEUR 137,223 to KEUR 150,790 (+9.9%) in the first nine months of the year 2022. The stable, positive sales development of NEXUS Group of recent years could be continued with that.

In the Healthcare Service Division, sales (unconsolidated) of KEUR 6,719 were achieved after KEUR 9,966 (9M-2021). In the previous year, we posted revenue of TEUR 1,839 for hardware in this segment, which we adjusted as a one-off effect. Without this turnover, the segment would have realised a sale of KEUR 8.127 in the first nine months of 2021, i.e. around 17,3% lower than in the previous year. This includes sales of KEUR 2,252 (previous year: KEUR 4,695) with the Healthcare Software segment.

On the other hand, sales (unconsolidated) increased from KEUR 132,002 (9M-2021) to KEUR 146,378 (+10.9%) in the Healthcare Software Division. This includes sales of KEUR 55 (previous year: KEUR 50) with the Healthcare Service segment. The values include the figures Zwicky Electronic AG, HeimSoft Solutions AG, oneICT AG, ANT-Informatik AG, acquisitions of business Centrasys Suite und Care Solutions, ITR Software GmbH, which were consolidated for the first time and contributed to about 3.96% of the growth of the NEXUS Group (KEUR 5.359).

IFMS GmbH and the acquisition of business On-Lab GmbH have not yet had a significant impact on the revenue and the result of the NEXUS Group.

We respect to the regional development of sales, we were able to increase sales in Germany by 7.1% to KEUR 79,239 (9M-2021): KEUR 73,955). In international business, we achieved sales of KEUR 71,551 in the first nine months of the year 2022 compared to KEUR 63,268 in the previous year (+13.1%). Sales in Switzerland (+14.9%), the Netherlands (+20.1%), France (+8.4%) and Austria (+41.2%) were very strong.

Consolidated earnings before income interest and taxes (EBIT) developed very positively. They improved by 24.1% to KEUR 18,794 (9M-2021): KEUR 15,140). A value of KEUR 22,351 was achieved in EBITA and consequently was 19.9% over the value of previous year (9M-2021): KEUR 18,639). EBITDA reached KEUR 31,236 in the first nine months of the year 2022 (9M-2021): KEUR 27,605) and consequently was 13.2% higher than in the previous year. The non-recurring costs for the integration of the new companies in the first nine months of the year 2022 amounted to approx. KEUR 1,306.

Cash flow from operating activities amounted to KEUR 30,948 (9M 2021: KEUR 24,727) in the first nine months of the year 2022, which is 25.2% higher than in the previous year. This is a high value, which especially resulted from prepayments on projects and maintenance contracts


The consolidated surplus increased by 24.6% and amounted to KEUR 13,845 in the first nine months of the year 2022 following KEUR 11,110 (9M-2021). There is a slight decrease in the tax rate there. The undiluted result per share amounted to EUR 0.86 (previous year: EUR 0.69) (diluted: EUR 0.86; previous year: EUR 0.69).

Investments in tangible and intangible assets were made in the amount of KEUR 4,059 in the first nine months of the year 2022 (9M-2021): KEUR 4,113). This includes KEUR 1,773 (9M-2021): KEUR 2,015) for capitalizing software developments.

The balance sheet total increased from KEUR 247,341 to KEUR 333,668 compared to 31/12/2021 (34.9%). This increase is mainly attributable to the capital increase of TEUR 72.500. Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 153,837 following previously KEUR 152,312 (31/12/2021). Receivables from customers amount to KEUR 28,134 following KEUR 31,930 on 31/12/2021.

EMPLOYEES

NEXUS Group employed an average of 1,544 people in the first nine months (9M 2021: 1,445 employees).



CHANGES IN OWNERSHIP INTEREST

The following changes were implemented in the ownership interest structure:

The following changes were implemented in the ownership interest structure:

- + NEXUS Schweiz AG, a wholly owned subsidiary of Nexus AG, acquired 60% of the shares of oneICT AG, Wallisellen (Switzerland), on 09/02/2022. A put/call option contract exists for a further 40% of the shares.
- + ASTRAIA Software GmbH was renamed NEXUS / ASTRAIA GmbH on 04/03/2022.
- + NEXUS Schweiz AG acquired a further 25% of the shares of the subsidiary osoTec GmbH, Affoltern am Albis (Switzerland), on 16/03/2022 from the existing option agreement.
- + Nexus AG acquired 70% of the shares in IFMS GmbH, Institut für medizinische Software, Saarbrücken, on 18/03/2022 with closing on 31/05/2022 and the associated transfer of the shares as well as the initial consolidation on this date. A put/call option contract exists for a further 30% of the shares.
- + NEXUS Schweiz AG acquired a further 20% of the shares of the subsidiary Creativ Software AG, Widnau (Switzerland), on 18/03/2022 from the existing option agreement.
- + NEXUS / CSO GmbH was renamed NEXUS / REHA GmbH on 15/04/2022.
- + On 02/05/2022, DC-Systeme Informatik GmbH acquired the business operations of On-Lab GmbH as part of an asset deal.
- + Nexus AG acquired a further 10.94% of the shares of the subsidiary NEXUS POLSKA sp. z o.o., Poznan (Poland), on 09/05/2022 from the existing option agreement.
- + E&L medical Systems GmbH was renamed NEXUS / E&L GmbH on 11/05/2022.

- + NEXUS Schweiz AG acquired 100% of the shares of Zwicky Electronic AG, Bottighofen (Switzerland), on 31/05/2022.
- + NEXUS Schweiz AG acquired 100% of the shares of HeimSoft Solutions AG, Zollikofen (Switzerland), on 01/06/2022.
- + DC-Systeme Informatik GmbH was renamed NEXUS / DIGITAL PATHOLOGY GmbH and the registered office moved to Donaueschingen on 12/08/2022.
- + RVC Medical IT GmbH was renamed Nexus Enterprise Imaging GmbH on 12/09/2022.
- + Nexus AG acquired a further 0.19% of the shares of the subsidiary RVC Medical IT Holding B.V. (Niederlande), on 29/08/2022 from the existing option agreement.

Finance Highlights Q3 2022

- + 24.6% increase in the consolidated surplus from KEUR 11,110 (9M-2021) to KEUR 13,845
- + 24.1% increase in Group result for earnings before interest and taxes (EBIT) from KEUR 15,140 (9M-2021) to KEUR 18,794
- + 25.2% increase in operational cash flow in the first nine months from KEUR 24,727 (9M-2021) to KEUR 30,948
- + High net liquidity incl. financial disposition of KEUR 109,783

EVENTS AFTER THE BALANCE SHEET DATE

- + There were no events after the balance sheet date.

SALES BY REGION

	01/01/2022- 30/09/2022	01/01/2021- 30/09/2021	Change	01/07/2022- 30/09/2022	01/07/2021- 30/09/2021	Change
	KEUR	KEUR	%	KEUR	KEUR	%
Germany	79,239	73,955	7.1	26,695	25,418	5.0
Switzerland /Lichtenstein	32,985	28,710	14.9	10,901	9,015	20.9
Netherlands	18,583	15,478	20.1	6,262	5,409	15.8
Polen	5,437	6,274	-13.3	2,144	2,682	-20.1
France	5,227	4,821	8.4	1,797	1,361	32.0
Austria	3,178	2,250	41.2	758	704	7.7
Other countries	6,141	5,735	7.1	2,201	1,777	23.9
Total	150,790	137,223	9.9	50,758	46,366	9.5

SALES BY OPERATING SEGMENTS

	Healthcare Software		Healthcare Service		Consolidation		Group	
	01/01/2022- 30/09/2022	01/01/2021- 30/09/2021	01/01/2022- 30/09/2022	01/01/2021- 30/09/2021	01/01/2022- 30/09/2022	01/01/2021- 30/09/2021	01/01/2022- 30/09/2022	01/01/2021- 30/09/2021
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Sales to third parties	146,323	131,952	4,467	5,271	—	—	150,790	137,223
Sales between segments	55	50	2,252	4,695	-2,307	-4,745	—	—
Segment revenues	146,378	132,002	6,719	9,966	-2,307	-4,745	150,790	137,223

Group Information

CHANCES AND RISKS REPORT

Please refer to the explanations in the Annual Report of 31/12/2021 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

ACCOUNTING AND VALUATION METHODS

This interim report of the NEXUS Group of 30/09/2022 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account. The regulations of IAS 34 were observed in the interim report of 30/09/2022. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Notes to the Group Financial Report 2021. The same accounting and valuation methods were used in the Group Financial Report for the business year 2021. The report has not been audited.

Stock Market, Event and Financial Data

Investor Relations – Successful Together!

We rely on transparent, regular and timely communication in dialog with the capital market. Our goal is to build trust and work together with our investors on the success of NEXUS.

We provide our investors a wide range of opportunities to exchange ideas at conferences, road shows and one-on-one meetings.

Melanie Ilic

Investor Relations
Tel.: +49 771 22960-260
Fax: +49 771 22960-226
E-Mail: ir@nexus-ag.de



Company Profile

nexus/ag

Nexus AG develops and sells software solutions for the international healthcare market. With our core Hospital information system (NEXUS / HIS) and integrated diagnostic modules (NEXUS / DIS), we have a unique product range, which can cover almost all functional requirements of hospitals, psychiatric institutions, rehabilitation facilities and diagnostic centers within our own product families.


NEXUS employs approx. 1,650 people, is present in seven European countries with its own sites and serves customers in an additional 23 countries via certified dealers.

Thanks to continuously growing demand for NEXUS products, we have been able to build up a large customer base in recent years and regularly show increases in sales and results.


Stock market prices

- + Initial listing on 03/01/2022: 71,90 EUR
- + Highest price on 04/01/2022: 73,10 EUR
- + Stock market capitalization on 30/09/2022: 824,39 Mio. EUR
- + Closing price on 30/09/2022: 47,75 EUR

Financial calendar



Frankfurt stock exchange stock prices (1-year period)



NEXUS / PORTAL

The digital patient support

NEXUS / PORTAL provides support of patients via a competent treatment process and subsequently treating facilities. Patient empowerment thus becomes an integrated component of everyday hospitality work.

PATIENT EMPOWERMENT



Documents and data are provided to a patient during and after treatment. As a result, he always has an overview of the treatment process - transparency and control are ensured.

PROCESS

- 1 BEFORE treatment**
Online appointment scheduling, information about length of stays and upload of relevant patient information
→ Structuring of admission
- 2 DURING treatment**
Access to current findings and schedules from the treatment process → In the hospital
- 3 AFTER treatment**
Inquiry sheet and relevant documentation for subsequent treatment by general practitioners, in an institution or a rehabilitation facility
→ Easing the workload of general practitioners, rehabilitation facility

TOOLS

Intuitive and easy operation for patients!



Documents and forms for admission and information
Online appointment scheduling with reminder feature and check-in



Treatment-specific information, results from preliminary examinations, examination results, information about the treatment process



Image data, digital aftercare and doctors' letters

Before hospital admission

In the hospital

After discharge


PATIENT EMPOWERMENT

Advantage for hospitals

✓ Optimization of admission process (pre-admission, scheduling management)

✓ Simplified information to the patient

✓ Unnecessary repetition of information prevented



Consolidated Profit and Loss Account

	01/01/2022-30/09/2022	01/01/2021-30/09/2021	01/07/2022-30/09/2022	01/07/2021-30/09/2021
	KEUR	KEUR	KEUR	KEUR
Revenue	150,790	137,223	50,758	46,366
Capitalized development costs	1,773	2,015	591	675
Other operating income	5,375	3,417	1,917	1,492
Cost of goods sold	24,667	23,106	8,822	8,698
Staff costs	88,553	81,097	29,107	26,405
Other operating expenses	13,482	10,847	4,924	4,216
EBITDA	31,236	27,605	10,413	9,214
Depreciation	12,442	12,465	4,022	4,221
EBIT	18,794	15,140	6,391	4,993
Financial income	59	47	57	30
Financial expenses	974	861	525	629
EBT	17,879	14,326	5,923	4,394
Taxes	4,034	3,216	1,229	864
Consolidated net income	13,845	11,110	4,694	3,530
Consolidated net income apportioned to:				
– Nexus AG shareholders	13,525	10,932	4,417	3,404
– Non-controlling interests	320	178	277	126
Consolidated earnings per share				
Weighted average (undiluted) of issued shares in circulation (in thousands)	15,801	15,748	16,008	15,746
Weighted average (diluted) of issued shares in circulation (in thousands)	15,801	15,748	16,008	15,746
Undiluted in EUR	0.86	0.69	0.28	0.22
Diluted in EUR	0.86	0.69	0.28	0.22

Consolidated Balance Sheet

ASSETS	30/09/2022	31/12/2021
	KEUR	KEUR
Non-current assets		
Goodwill	108,720	102,927
Other intangible assets	43,330	46,597
Fixed assets	11,881	11,938
Right-of-use assets	18,131	16,475
Deferred tax assets	1,787	2,788
Other financial assets	407	393
Total non-current assets	184,256	181,118
Current assets		
Inventories	1,080	1,691
Trade and other receivables	28,134	31,930
Contract assets	4,540	2,234
Other non-financial assets	4,624	3,670
Other financial assets	91,251	526
Cash and cash equivalents	19,783	26,172
Total current assets	149,412	66,223
Total assets	333,668	247,341

LIABILITIES	30/09/2022	31/12/2021
	KEUR	KEUR
Equity		
Subscribed capital	17,265	15,815
Capital reserves	105,640	34,470
Retained earnings	106,238	95,863
Other comprehensive income	4,634	-6,827
Capital redemption reserve	-2,671	-529
Shareholders' equity attributable to parent	231,106	138,792
Non-controlling interests	3,825	3,611
Total equity	234,931	142,403
Non-current liabilities		
Pension obligations	5,456	16,295
Deferred tax liabilities	10,081	10,363
Other financial liabilities	7,094	6,211
Lease liabilities	13,819	12,072
Total non-current liabilities	36,450	44,941
Current liabilities		
Accrued liabilities	7,209	6,016
Deferred liabilities	14,707	13,399
Other non-financial liabilities	9,697	21,549
Trade payables	3,903	5,043
Other financial liabilities	1,527	5,384
Lease liabilities	4,574	4,559
Contract liabilities	20,670	4,047
Total current liabilities	62,287	59,997
Balance sheet total	333,668	247,341

Consolidated Cash Flow Statement

	01/01/2022-30/09/2022	01/01/2021-30/09/2021
1. Cash flow from operating activities	KEUR	KEUR
EBIT	18,794	15,140
Depreciation (+)/amortization (-) on intangible assets and fixed assets	8,963	8,717
Depreciation (+) on rights of use leased assets	3,479	3,748
Other non-operating expenses (+)/income (-)	-1,060	766
Increase (-)/decrease (+) in inventory	719	-151
Gains (-)/losses (+) on the disposal of assets and investments	-	-53
Increase (-)/decrease (+) in receivables and other assets	-182	-6,220
Increase (+)/decrease (-) in provisions	1,029	-698
Increase (+)/decrease (-) in liabilities	3,847	7,147
Interest paid (-) / interest received (+)	-979	-303
Income taxes paid (-) / income tax refunds (+)	-3,662	-3,366
	30,948	24,727
2. Cash flow from investment activities		
Payments (-) for investments in intangible assets and property, plant and equipment	-4,059	-4,113
Proceeds (+) from the disposal of intangible assets and property, plant and equipment	-	53
Payments (-) for the acquisition of consolidated companies less the funds acquired	-2,951	-15,362
Payments (-)/proceeds (+) from the acquisition / divestment of shortterm financial dispositions	-90,000	1,728
	-97,010	-17,694
3. Cash flow from financing activities		
Incoming payments from capital increases	72,500	-
Payments (-) for purchase of non-controlling interests for already consolidated companies	-4,641	-1,555
Payments (-) for redemption of lease liabilities	-3,660	-3,427
Payments (-) for redemption of loan liabilities	-	-721
Dividends paid (-)	-3,153	-2,992
Dividends paid to non-controlling interests (-)	-121	-44
Payments (-) for the purchase of treasury stock	-2,161	-528
Proceeds (+) from the sale of treasury stock	19	135
	58,783	-9,132
Change in cash and cash equivalents	-7,279	-2,099
Effect of exchange rate changes on cash and cash equivalents	890	-608
Cash and cash equivalents at the start of the period	26,172	26,449
Cash and cash equivalents at the end of the period	19,783	23,742
Composition of cash and cash equivalents		
Cash and bank balances	19,783	23,742
Cash and bank balances incl. shortterm financial disposition	109,783	23,742

__ Statement from the Legal Representatives

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 08/11/2022

Nexus AG

The Executive Board